Introduction
Abdominal Henoch-Schönlein purpura (HSP)—a severe subtype of pediatric vasculitis—poses significant challenges due to its potential for life-threatening complications like intestinal hemorrhage and perforation. Traditional corticosteroid monotherapy, while effective, often falls short in managing refractory cases and carries risks of long-term side effects. A groundbreaking study from Xingyi People’s Hospital in China offers new hope by demonstrating the synergistic benefits of combining mycophenolate mofetil (MMF) with prednisone in treating this condition.
Background: The Need for Improved Therapies
HSP in children is characterized by immune-mediated inflammation, leading to symptoms such as abdominal pain, skin purpura, and joint pain. While glucocorticoids like prednisone suppress systemic inflammation, their prolonged use increases vulnerability to infections, growth impairment, and gastrointestinal complications. Emerging evidence suggests that T-cell dysregulation drives HSP pathogenesis, prompting researchers to explore immunomodulatory agents like MMF—a drug traditionally used in organ transplantation and lupus nephritis.
Study Design: A Randomized Controlled Trial
Researchers conducted a randomized trial involving 80 children (ages 3–14) diagnosed with abdominal HSP between February 2022 and February 2024. Participants were divided into two groups:
- Control Group: Received prednisone alone (starting at 1 mg/kg/day, tapered gradually).
- Intervention Group: Received MMF (15–20 mg/kg/day in two divided doses) plus prednisone (same dosing regimen).
Key outcomes measured included:
- Clinical efficacy (symptom resolution, remission rates).
- Inflammatory markers (IL-23, IL-34, TNF-α).
- Safety profile (adverse events like gastrointestinal bleeding or infection).
Results: A Clear Advantage for Combination Therapy
- Superior Efficacy
- The intervention group achieved a 92.5% total response rate compared to 72.5% in the control group (p=0.019).
- Symptoms like abdominal pain, purpura, and joint pain resolved significantly faster in the MMF-prednisone group (p<0.05 across all measures).
- Inflammation Suppression
- Post-treatment levels of pro-inflammatory cytokines (IL-23, IL-34, TNF-α) dropped sharply in both groups—but the decline was more pronounced with combination therapy (p<0.05 for all biomarkers).
- Enhanced Safety Profile
- Adverse events (e.g., gastrointestinal ulcers, bleeding, respiratory infections) occurred in 10% of the intervention group versus 32.5% in the control group (p=0.014).
Mechanisms Behind the Success
MMF’s dual action explains its synergy with prednisone:
- Immunosuppression: By inhibiting inosine monophosphate dehydrogenase (IMPDH), MMF curtails lymphocyte proliferation, addressing the T-cell dysregulation central to HSP.
- Steroid-Sparing Effect: Reduced reliance on high-dose prednisone lowers the risk of growth suppression, osteoporosis, and metabolic disturbances.
Clinical Implications and Future Directions
This study positions MMF-prednisone as a viable first-line therapy for severe abdominal HSP, particularly in patients at high risk of steroid-related complications. However, researchers note limitations:
- Small sample size (n=80).
- Short follow-up period (3 months).
Future trials should assess long-term outcomes and explore genetic factors influencing treatment response.
Conclusion
The combination of MMF and prednisone represents a paradigm shift in managing pediatric abdominal HSP. By enhancing efficacy, accelerating recovery, and mitigating risks, this regimen could become the new standard of care. Parents and clinicians alike should stay informed about these advances to optimize treatment decisions for affected children.
Keywords: Abdominal Henoch-Schönlein purpura, mycophenolate mofetil, prednisone, pediatric vasculitis, immunomodulation.


Comments are closed